Search research articles
Contact Us
Filters
Showing results (11-20 of 143) with videos related to
Page
of 15
Sort By:
Circulation
|
May 13, 2024
Win Ratio: A Seductive But Potentially Misleading Method for Evaluating Evidence from Clinical Trials
Javed Butler, Norman Stockbridge, Milton Packer
Pharmacoepidemiology and Drug Safety
|
July 5, 2012
Removal from labeling of 60-mg citalopram dose
Robert Temple, Thomas Laughren, Norman Stockbridge
European Journal of Heart Failure
|
September 20, 2017
Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy
Javed Butler, Norman Stockbridge, Mihai Gheorghiade
Cellular Signalling
|
April 24, 2012
How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?
Gowraganahalli Jagadeesh, Pitchai Balakumar, Norman Stockbridge
Circulation
|
November 16, 2020
Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices
Sanjay Kaul, Norman Stockbridge, Javed Butler
Nature Reviews. Drug Discovery
|
February 20, 2016
Evolution of strategies to improve preclinical cardiac safety testing
Gary Gintant, Philip T Sager, Norman Stockbridge
Journal of Electrocardiology
|
August 16, 2016
Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs
Jose Vicente, Norman Stockbridge, David G Strauss
JACC. Basic to Translational Science
|
September 1, 2018
Resourcing Drug Development Commensurate With its Public Health Importance: The Road Ahead
Mona Fiuzat, Norman Stockbridge, Robert M Califf
Drug Safety
|
March 13, 2016
Universal Correction for QT/RR Hysteresis
Marek Malik, Lars Johannesen, Katerina Hnatkova, et al.
Cell Stem Cell
|
July 8, 2017
The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery
Gary Gintant, Bernard Fermini, Norman Stockbridge, et al.
Page
of 15
Search research articles
Search
Showing results (11-20 of 143) with videos related to
Sort By:
Page
of 15
Circulation
|
May 13, 2024
Win Ratio: A Seductive But Potentially Misleading Method for Evaluating Evidence from Clinical Trials
Javed Butler, Norman Stockbridge, Milton Packer
Pharmacoepidemiology and Drug Safety
|
July 5, 2012
Removal from labeling of 60-mg citalopram dose
Robert Temple, Thomas Laughren, Norman Stockbridge
European Journal of Heart Failure
|
September 20, 2017
Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy
Javed Butler, Norman Stockbridge, Mihai Gheorghiade
Cellular Signalling
|
April 24, 2012
How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?
Gowraganahalli Jagadeesh, Pitchai Balakumar, Norman Stockbridge
Circulation
|
November 16, 2020
Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices
Sanjay Kaul, Norman Stockbridge, Javed Butler
Nature Reviews. Drug Discovery
|
February 20, 2016
Evolution of strategies to improve preclinical cardiac safety testing
Gary Gintant, Philip T Sager, Norman Stockbridge
Journal of Electrocardiology
|
August 16, 2016
Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs
Jose Vicente, Norman Stockbridge, David G Strauss
JACC. Basic to Translational Science
|
September 1, 2018
Resourcing Drug Development Commensurate With its Public Health Importance: The Road Ahead
Mona Fiuzat, Norman Stockbridge, Robert M Califf
Drug Safety
|
March 13, 2016
Universal Correction for QT/RR Hysteresis
Marek Malik, Lars Johannesen, Katerina Hnatkova, et al.
Cell Stem Cell
|
July 8, 2017
The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery
Gary Gintant, Bernard Fermini, Norman Stockbridge, et al.
Page
of 15